Morgan Stanley Adma Biologics, Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 1,961,585 shares of ADMA stock, worth $32.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,961,585

Previous 4,913,928 60.08%

Holding current value

$32.9 Million

Previous $97.5 Million 63.36%

% of portfolio

0.0%

Previous 0.01%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	SELL	$17.6 - $24.51 $52 Million - $72.4 Million	-2,952,343 Reduced 60.08%	1,961,585 $35.7 Million
Q1 2025 May 15, 2025	SELL	$15.44 - $20.61 $9.58 Million - $12.8 Million	-620,409 Reduced 11.21%	4,913,928 $97.5 Million
Q4 2024 Feb 14, 2025	SELL	$15.62 - $22.62 $47.9 Million - $69.3 Million	-3,065,281 Reduced 35.64%	5,534,337 $94.9 Million
Q3 2024 May 14, 2025	BUY	$11.21 - $20.03 $44.9 Million - $80.1 Million	4,001,131 Added 87.01%	8,599,618 $172 Million
Q3 2024 Nov 14, 2024	BUY	$11.21 - $20.03 $44.9 Million - $80.1 Million	4,001,131 Added 87.01%	8,599,618 $172 Million
Q2 2024 May 14, 2025	SELL	$5.98 - $11.18 $5.6 Million - $10.5 Million	-935,850 Reduced 16.91%	4,598,487 $51.4 Million
Q2 2024 Oct 17, 2024	BUY	$5.98 - $11.18 $4.67 Million - $8.74 Million	781,763 Added 20.48%	4,598,487 $51.4 Million
Q2 2024 Aug 14, 2024	BUY	$5.98 - $11.18 $4.67 Million - $8.74 Million	781,763 Added 20.48%	4,598,487 $51.4 Million
Q1 2024 Oct 17, 2024	SELL	$4.4 - $6.74 $3.44 Million - $5.27 Million	-781,763 Reduced 17.0%	3,816,724 $25.2 Million
Q1 2024 Aug 16, 2024	BUY	$4.4 - $6.74 $143,180 - $219,326	32,541 Added 0.86%	3,816,724 $25.2 Million
Q1 2024 May 15, 2024	BUY	$4.4 - $6.74 $143,180 - $219,326	32,541 Added 0.86%	3,816,724 $25.2 Million
Q4 2023 Aug 16, 2024	SELL	$3.08 - $4.52 $2.51 Million - $3.68 Million	-814,304 Reduced 17.71%	3,784,183 $17.1 Million
Q4 2023 Feb 13, 2024	SELL	$3.08 - $4.52 $4.48 Million - $6.58 Million	-1,455,188 Reduced 27.77%	3,784,183 $17.1 Million
Q3 2023 Nov 15, 2023	BUY	$3.47 - $4.61 $5.1 Million - $6.78 Million	1,470,953 Added 39.03%	5,239,371 $18.8 Million
Q2 2023 Aug 14, 2023	SELL	$3.12 - $4.22 $2.18 Million - $2.94 Million	-697,684 Reduced 15.62%	3,768,418 $13.9 Million
Q1 2023 May 15, 2023	BUY	$3.01 - $3.87 $3.73 Million - $4.79 Million	1,237,766 Added 38.34%	4,466,102 $14.8 Million
Q4 2022 Feb 14, 2023	BUY	$2.47 - $3.88 $2.15 Million - $3.38 Million	870,715 Added 36.93%	3,228,336 $12.5 Million
Q3 2022 Nov 14, 2022	BUY	$2.03 - $2.86 $3.04 Million - $4.29 Million	1,498,858 Added 174.54%	2,357,621 $5.73 Million
Q2 2022 Oct 27, 2022	BUY	$1.43 - $2.2 $1.04 Million - $1.6 Million	727,377 Added 553.62%	858,763 $1.7 Million
Q2 2022 Aug 15, 2022	BUY	$1.43 - $2.2 $1.04 Million - $1.6 Million	727,377 Added 553.62%	858,763 $1.7 Million
Q1 2022 Oct 27, 2022	SELL	$1.28 - $1.83 $931,042 - $1.33 Million	-727,377 Reduced 84.7%	131,386 $240,000
Q1 2022 May 13, 2022	SELL	$1.28 - $1.83 $228,663 - $326,916	-178,643 Reduced 57.62%	131,386 $240,000
Q4 2021 Feb 14, 2022	SELL	$1.09 - $1.66 $358,070 - $545,318	-328,505 Reduced 51.45%	310,029 $436,000
Q3 2021 Nov 15, 2021	BUY	$1.13 - $1.65 $721,543 - $1.05 Million	638,534 New	638,534 $721,000

Others Institutions Holding ADMA

# of Institutions

407

Shares Held

193M

Call Options Held

2.13M

Put Options Held

1.59M

View Full List

About ADMA BIOLOGICS, INC.

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $3.29B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

More about ADMA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account